logo
Share SHARE
FONT-SIZE Plus   Neg

Bayer's Xarelto Approved In EU For Preventing Stroke In Patients With AF

Bayer AG (BYR.L,BAYRY.PK,BAYZF.PK) said Bayer HealthCare's oral anticoagulant Xarelto (rivaroxaban) has been approved by the European Commission for use in two new indications, making it the only new oral anticoagulant approved in three indications across all 27 EU member states.

Xarelto is approved for preventing stroke and systemic embolism in adult patients with non-valvular atrial fibrillation, or AF, with one or more risk factors and for treatment of deep vein thrombosis, or DVT, and prevention of recurrent DVT and pulmonary embolism following an acute DVT in adults. It is also approved for prevention of Venous Thromboembolism, or VTE, in adult patients undergoing elective hip or knee replacement surgery.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Amazon.com Inc. is working on developing a pair of smart glasses that would allow to summon and interact with virtual assistant Alexa while wearing the device, the Financial Times reported, citing people familiar with the plans. The glasses, which would be required to be connected wirelessly to a smartphone to work, is reportedly designed to look like a regular pair of spectacles. Employees at Bombardier Inc.'s aerospace plant in Toronto plan to walk out of the facility on Wednesday morning. The move is an attempt to put pressure on Boeing Co. to drop a trade complaint against the Canadian plane and train maker. The Baltimore Ravens, a professional American football team, postponed its "DNA Day" event just hours before this season's home opener last Sunday. Orig3n Inc., a Boston-based biotech company sponsoring the event, said in a statement that it is "working to address questions from officials from the state of Maryland."
comments powered by Disqus
Follow RTT